Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 7/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 6/20 | 0.46 |
| ▸ | ACP1 | P24666 | 1/20 | 0.46 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.45 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.45 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4511786 | 1.00 | MEN1 (0.46) | MEN1KMT2ARXFP1CHEK2CHEK1 | |
| SCHEMBL4511790 | 1.00 | MEN1 (0.46) | MEN1KMT2ARXFP1CHEK2CHEK1 | |
| SCHEMBL4514611 | 0.95 | ACP1 (0.51) | MEN1KMT2ARXFP1CHEK2CHEK1 | |
| SCHEMBL4514616 | 0.95 | ACP1 (0.51) | MEN1KMT2ARXFP1CHEK2CHEK1 | |
| SCHEMBL4514622 | 0.95 | ACP1 (0.51) | MEN1KMT2ARXFP1CHEK2CHEK1 | |
| SCHEMBL8227557 | 0.95 | ACP1 (0.51) | MEN1KMT2ARXFP1CHEK2CHEK1 | |
| SCHEMBL4510863 | 0.93 | ACP1 (0.46) | MEN1KMT2ARXFP1CHEK2CHEK1 | |
| SCHEMBL4510864 | 0.93 | ACP1 (0.46) | MEN1KMT2ARXFP1CHEK2CHEK1 | |
| SCHEMBL4510858 | 0.93 | ACP1 (0.46) | MEN1KMT2ARXFP1CHEK2CHEK1 | |
| SCHEMBL4508015 | 0.93 | MEN1 (0.47) | MEN1KMT2ARXFP1CHEK2CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247519-A1 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-10-01 | — | — | US | disclosed |
| US-20090247519-A1 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-10-01 | — | — | US | disclosed |
| US-20090247519-A1 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-10-01 | — | — | US | disclosed |
| WO-2007125331-A2 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247519-A1 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | PKD2, PKD1, AADAT | MEN1 4237/4885KMT2A 230/4885RXFP1 3771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.